Sofwave Medical: Can the Body Platform Really Become a Second Engine?
Sofwave’s body expansion is no longer just a presentation-deck story: Lift HD sits on the existing console, Pure Impact VIP launched as a standalone system, and early clinical data already exists. But without disclosure on revenue, adoption, and utilization, the body category still looks more like the infrastructure for a second engine than a second engine already in place.
The Body Story Is No Longer Just Slideware
The main article argued that Sofwave has already proved it can sell, generate usage, and reach profitability. The open question was whether the body category is only a convenient extension of that story, or a new economic layer that can reduce dependence on the facial platform. This continuation isolates that exact issue.
The short answer is that the body category is more real than a superficial read suggests, but still not proven enough to be called a second engine. On one side, 2025 gave the company a clear chain of approvals, launches, and clinical work: Lift HD reached the market as a larger body applicator on the same console, Pure Impact widened from arms into multiple muscle groups and multiple body areas, and in July 2025 Pure Impact VIP received FDA clearance as a standalone system and was launched in Q4. On the other side, the company still does not disclose how much of 2025 revenue came from body, how many VIP units were sold, what Lift HD’s attach rate looks like on the installed base, or how much of recurring revenue is already tied to these newer use cases.
That matters even more because Sofwave is already sitting on a meaningful commercial base. In management’s presentation the company shows roughly 2,700 systems sold since commercialization, roughly 770 thousand cumulative treatments, and usage fees equal to 43% of 2025 revenue. That makes the attraction of body obvious: Lift HD can try to deepen usage on infrastructure that already exists, while Pure Impact VIP adds another recurring billing rail. The problem is that the reporting package proves the infrastructure for that story, not the actual pace of adoption.
| Milestone | What actually happened | Why it matters economically |
|---|---|---|
| Lift HD | Approved in 2024 and launched in 2025 as a larger body applicator | This is the simplest expansion path on the existing console base |
| Pure Impact for arms | An arms indication was added in 2024 | The body category moved from a narrower use case toward broader practical relevance |
| Broader Pure Impact body use | In 2025 the company added abdomen, arms, thighs, and buttocks across multiple muscle groups at the same time | The product expanded from a point module into a broader body platform |
| Pure Impact VIP | Cleared in July 2025 as a standalone system and launched in Q4 2025 | This opened a separate commercialization path, not only an extension of the existing device |
Lift HD: The Easier Economic Extension
Lift HD looks like the lower-friction commercial move. The FDA cleared the treatment applicator in May 2024, and the annual report describes it as being based on the same SUPERB technology, covering a larger treatment area, and providing a better fit for larger body areas such as the buttocks, thighs, and arms, all without requiring any change to the existing Sofwave console. The 2026 investor presentation sharpens that point further: the new applicator doubles the area of each ultrasound transducer, increases controlled thermal injury in the skin, and improves treatment speed for large body areas.
Economically, that matters because Lift HD rests on Sofwave’s most proven model rather than on an entirely new market motion. Sofwave sells the system and then sells pulses consumed with each treatment. The company also notes that pulses are a digital component sold only by Sofwave, and that this layer already represented 43% of 2025 revenue. So Lift HD does not need to rebuild the distribution model or the ROI conversation with the physician. If a clinic that already owns a console can add faster body treatments on the same infrastructure, the path to deeper usage is relatively short.
But that is still economic logic, not commercialization proof. There is no disclosure on how many clinics actually added Lift HD, how many body treatments it generated, or whether it materially increased pulse consumption. So for now Lift HD looks like the best candidate to improve customer economics, not proof that this improvement has already happened.
Pure Impact VIP: The Bigger Move, and the More Demanding One
If Lift HD is an extension of the existing base, Pure Impact VIP is already an attempt to build a separate layer. The company describes Pure Impact as an EMS product for muscle toning and strengthening. In 2024 it received an arms indication, in April 2025 it broadened into abdomen, arms, thighs, and buttocks across multiple muscle groups at the same time, and in July 2025 the FDA cleared Pure Impact VIP as a standalone product. In management’s presentation it is already framed as a standalone unit launched in Q4 2025 and designed for continuous whole-body muscle progression rather than short-term results.
This is a crucial point for product economics. The annual report says the Pure Impact business model is based on pre-purchased treatment hours, with a standard protocol of four 30-minute treatments. At the same time, the company says the system can treat up to six muscle groups simultaneously in a single 30-minute treatment without manually repositioning electrodes, and the investor presentation goes one step further by framing simultaneous skin and muscle treatment as an attractive provider business model. If that works, this is not just one more indication. It is a path toward higher revenue per visit, per patient, and per treatment room.
But this is also where the friction starts. Pure Impact VIP can be combined with Sofwave, yet it is also a standalone unit separate from the ultrasound platform. Unlike Lift HD, this is not simply another applicator sold onto a console that is already in the clinic. It is a separate purchase decision, a separate footprint in the clinic, and a separate usage case that needs to prove itself. In plain terms, Lift HD is an installed-base extension. VIP is a full commercialization test.
It also does not arrive free of structural cost. In the related-party section, the company says the Excita license, tied to technology controlled by Shimon Eckhouse, requires royalties of 5% on net sales of licensed products and 2.5% on net sales of combined products. In 2025 Sofwave recorded USD 217 thousand of royalty expense, paid USD 249 thousand, and ended the year with a USD 56 thousand payable tied to Pure Impact sales. That is the clearest sign that the body category has already entered the income statement, but also that it will not enjoy the same marginal economics as the pulse model.
That same royalty line also says something about current scale. USD 217 thousand is not a number that shifts Sofwave’s annual economics by itself. So anyone trying to treat 2025 as proof that body already moved the consolidated model is simply moving too early. As of year-end 2025, the body category is present in the filings, but not yet large enough on disclosed evidence to reshape the consolidated picture on its own.
| Body layer | What is already supported in the filings | Where the economic upside sits | What friction still remains |
|---|---|---|---|
| Lift HD | A larger applicator on the same console, with no change to the existing product line | More body treatments on an installed base that already exists, so the upside sits in deeper usage | No disclosure on attach rate, usage pace, or revenue contribution |
| Pure Impact VIP | A standalone system, multi-muscle treatment at the same time, and treatment-hour billing | A second recurring billing rail and a possible combined skin-and-muscle workflow | A separate selling motion, royalty leakage, and no disclosure on units or revenue scale |
The Clinical Evidence Is Enough to Open the Door, Not Close the Case
The company is not relying only on marketing here. The annual report shows two clinical tracks that directly matter for the thesis. The first is a 2024-2025 post-marketing upper-arm study combining one to two Sofwave treatments with four Pure Impact treatments across 47 patients at four US research sites. All 47 completed the treatment series, 42 also completed the two follow-up visits, 93% showed improvement in the treated area at both follow-ups, and arm-muscle strength improved significantly. That matters because it supports the exact combined workflow the company wants to sell, skin and muscle together.
The second track is a 2025 post-marketing study on abdomen, thighs, and glutes with 38 patients, 19 in treatment and 19 in control. Here there is both a control arm and functional testing. The investor presentation shows sharp separation: prone hip extension repetitions improved by 69% at week 5 and 65% at week 9 versus declines of 3% and 9% in the control group; paced curl-up repetitions improved by 42% and 33% versus 3% and 7%; seated quadriceps extension repetitions improved by 53% and 45% versus 5% and 2%; and side-plank endurance improved by 74% and 71% versus declines of 13% and 8%.
Those figures are good enough to say Sofwave is not presenting an empty body story. There is a real functional signal, and there is also some evidence that the combination of Sofwave and Pure Impact can work as one workflow. But it would be a mistake to confuse that with commercialization proof. The studies are still small, some are post-marketing, and none of them tells us how many clinics adopted the protocol, at what price point, or how repeatable it is commercially. The clinical case is partly proven. The economic case still is not.
The same caution applies to the GLP-1 narrative in the presentation. Management uses it to frame the body solution as a response to a new demand pool. That may be a smart commercial framing, but the 2025 reporting package still does not provide a quantitative bridge from that demand narrative to sales, treatment hours, or recurring revenue.
Bottom Line
It is now fair to say that Sofwave’s body category has moved past the fantasy stage. There are approvals, launches, a billing model, royalty expense, and early clinical evidence. But it is still not fair to call it a second engine. To get there, the market will need to see more than additional GLP-1 slides and more than extra regulatory clearances. It will need adoption evidence: broader Lift HD use on the installed base, repeat purchases of treatment hours in Pure Impact, and above all some indication that physicians are actually integrating the two products into one commercial workflow.
If the choice has to be made already today, Lift HD looks like the nearer and simpler path because it sits on the existing console base and on the pulse model that has already proved itself. Pure Impact VIP looks like the bigger opportunity because it expands Sofwave from skin into muscle and opens a fuller body category, but it also carries more commercial friction and more margin friction. So as of year-end 2025, the body category is still a thesis in progress, not a closed proof.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.